Regen-cov And Ronapreve Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The regen-cov and ronapreve market research report is one of a series of new reports that provides regen-cov and ronapreve market statistics, including regen-cov and ronapreve industry global market size, regional shares, competitors with a regen-cov and ronapreve market share, detailed regen-cov and ronapreve market segments, market trends and opportunities, and any further data you may need to thrive in the regen-cov and ronapreve industry. This regen-cov and ronapreve market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the rising prevalence of chronic and complex diseases, rising incidence of infectious diseases, rising prevalence of viral infections, rising incidence of zika virus infections, and rising incidence of respiratory infections. Major trends in the forecast period include the adoption of bispecific antibodies, remote diagnostics and monitoring, a focus on emerging and neglected viral infections, advances in diagnostic testing, and the adoption of molecular diagnostic techniques.

The growth of the regen-cov and ronapreve market is expected to be driven by the rising incidence of infectious diseases. Infectious diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread through contact, air, water, or contaminated food. The increase in these diseases is influenced by factors such as climate change, which extends the range of disease vectors such as mosquitoes, and globalization, which accelerates the spread of pathogens across borders due to increased travel. Regen-Cov (Ronapreve) is a monoclonal antibody cocktail designed to treat COVID-19 by targeting the SARS-CoV-2 virus and preventing severe illness, particularly in high-risk patients. For example, in November 2024, the National Library of Medicine reported that between November 5 and 11, 167,369 people in England tested positive for COVID-19, marking an 11% increase from the previous week. The positivity rate remained steady at 9.6%, close to the 9.7% from the prior week. This rising incidence of infectious diseases is expected to continue driving the growth of the regen-cov and ronapreve market.

The market growth for regen-cov and ronapreve is also being fueled by rising healthcare investments. Healthcare investments refer to the financial resources allocated to the healthcare sector, which includes funding for medical technologies, pharmaceuticals, healthcare facilities, and services. The increase in healthcare investments is driven by factors such as the aging population, which raises the demand for healthcare services, and advancements in medical technology that promote innovation and enhance patient care. These investments support the development and distribution of regen-cov and ronapreve, funding clinical trials, expanding production, securing regulatory approvals, and improving accessibility. For instance, in January 2024, the National Institutes of Health reported that in 2022, healthcare spending in the US rose by 4.1%, reaching $4.5 trillion, a faster growth rate than the 3.2% increase in 2021. This growth in healthcare investments is contributing to the expansion of the regen-cov and ronapreve market.

The driving the market’s growth is the regulatory approvals obtained to expand the use of regen-cov and ronapreve for additional indications and across various regions. Regulatory approvals are formal authorizations granted by health authorities, such as the FDA or EMA, allowing a drug or treatment to be legally sold and used after proving its safety, efficacy, and quality through clinical evaluations. For example, F. Hoffmann-La Roche AG, a Swiss pharmaceutical company, received approval for Ronapreve, a monoclonal antibody treatment, for the treatment of non-hospitalized COVID-19 patients and for the prevention of the disease. This approval was granted in collaboration with Regeneron Pharmaceuticals. Ronapreve is indicated for adults and adolescents aged 12 and older who are at increased risk of severe COVID-19 but do not require supplemental oxygen. Clinical studies have shown that Ronapreve significantly reduces the risk of hospitalization and death and can prevent symptomatic COVID-19 in individuals exposed to infected persons. These regulatory approvals are helping to drive market growth by expanding the treatment’s use and accessibility.

The key players operating in the regen-cov and ronapreve market are F. Hoffmann-La Roche AG and Regeneron Pharmaceuticals.

North America was the largest region in the regen-cov and ronapreve market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in regen-cov and ronapreve report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the regen-cov and ronapreve market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Regen-Cov and Ronapreve are monoclonal antibody therapies that combine casirivimab and imdevimab, designed to neutralize SARS-CoV-2 by targeting its spike protein, preventing the virus from entering cells. These treatments are authorized for managing mild-to-moderate COVID-19 in high-risk patients and as post-exposure prophylaxis, effectively reducing hospitalization and mortality rates.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for Regen-Cov and Ronapreve include the treatment of mild to moderate COVID-19, post-exposure prophylaxis (PEP), and pre-exposure prophylaxis (PrEP). Treating mild to moderate COVID-19 involves administering medication to patients diagnosed with COVID-19 who have mild to moderate symptoms and are not hospitalized. These therapies are distributed through hospitals, outpatient clinics, and home healthcare, serving a range of patients, including pediatric, adult, and geriatric populations.

The regen-cov and ronapreve market consists of sales of monoclonal antibodies, intravenous (IV) infusion solutions, and subcutaneous (SubQ) injection solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.